Jazz Pharmaceuticals (JAZZ) Stock Forecast & Price Target

Jazz Pharmaceuticals is supported by a diversified commercial base and a strengthening oncology franchise, with total sales estimated to grow from $2.4B in 2020 to $4.3B in 2026 and FY26 revenue guidance reiterated at $4.25B-$4.50B. The positive view is driven by strong execution across Xywav, Epidiolex, and Zepzelca, plus Ziihera’s expanding opportunity after its 1L HER2+ GEA approval, where management raised peak sales potential to $3B-$5B from $2B+ and sees broad utility across additional tumors. Even with some Xyrem erosion and sleep-franchise uncertainty, the company’s growing commercial footprint, patient support infrastructure, and multiple pipeline catalysts leave meaningful upside from both marketed products and internal and external business development.

Jazz Pharmaceuticals is exposed to meaningful fundamental downside because its cash flow is heavily dependent on the Xyrem franchise, and any generic erosion or patent failure could materially weaken the company’s core earnings base. The stock also faces significant regulatory and clinical uncertainty, including the possibility that Phase 3 Zepzelca trials do not show benefit in first-line SCLC and that early pipeline assets such as JZP150 and JZP385 produce negative readouts. Commercial execution risks remain elevated as Epidiolex could face generic competition as early as after expiration of ODE in 2027, while Rylaze growth, Xywav share, and broader capital access may all disappoint.